BRIDGEBIO PHARMA, INC.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

Filing · LD-2 quarterly report Q4 amendment

Reporting period

4th Quarter 2024

Oct 1 - Dec 31 · Posted Jul 17, 2026

Expenses

$330,000

What this organization spent lobbying with its own staff. The filing did not state which of the three LDA accounting methods produced this number, so it is not comparable with another filer's.

Client based in

California

Official filing document

Lobbyists on this filing 1

MICHAEL CALVO New on this filing

Previously held: Rep. Taylor (NC-11) Intern, Leg. Correspondent, Leg. Asst. Rep. McHenry (NC-10) Policy Advisor Rep. Gingrey (GA-11) Senior Leg. Asst., Senior Policy Advisor, Leg. Director, Deputy Chief of Staff Rep. Hice (GA-10) Leg. Director

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted

House of Representatives
Senate

Only the chambers were recorded for this filing. Any agencies it named are in the official document.

Lobbying activity 1

Pharmacy

Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies Scientific EXPERT Act of 2024 - H.R.9979 H.R.9979 - Scientific EXPERT Act of 2024 H.R.10545 - American Relief Act, 2025

Bills named in this filing 5

H.R. 7384
Creating Hope Reauthorization Act of 2024
H.R. 3433
Give Kids a Chance Act of 2024
S. 4583
Creating Hope Reauthorization Act of 2024
H.R. 9979
Scientific EXPERT Act of 2024
H.R. 10545
American Relief Act, 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.